@article{466960064add4a2184cbddb698ebfeeb,
title = "Neoadjuvant therapy for breast cancer",
abstract = "Objective: To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I–III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area. Methods: Data from the High Resolution Study conducted in 7 Italian cancer registries were used; they are a representative sample of incident cancers in the study period (2009–2013). Included were 3546 women aged ",
keywords = "Breast cancer, multidisciplinary, neoadjuvant therapy, adult, aged, Article, breast cancer, cancer chemotherapy, cancer grading, cancer hormone therapy, cancer incidence, cancer registry, cancer screening, cancer staging, cancer surgery, female, geography, human, human epidermal growth factor receptor 2 positive breast cancer, Italy, luminal A breast cancer, luminal B breast cancer, major clinical study, medical history, molecularly targeted therapy, partial mastectomy, triple negative breast cancer, breast tumor, mammography, middle aged, multimodality cancer therapy, odds ratio, treatment outcome, very elderly, tumor marker, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Breast Neoplasms, Combined Modality Therapy, Female, Humans, Mammography, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Odds Ratio, Treatment Outcome",
author = "L. Mangone and P. Mancuso and G. Tagliabue and R.A. Filiberti and G. Carrozzi and S. Iacovacci and W. Mazzucco and R. Tumino and P. Minicozzi and M. Sant and {Giorgi Rossi}, P.",
note = "Cited By :1 Export Date: 26 February 2020 CODEN: TUMOA Correspondence Address: Mangone, L.; Epidemiology Unit, Azienda Unit{\`a} Sanitaria Locale-IRCCS Reggio EmiliaItaly; email: mangone.lucia@ausl.re.it Chemicals/CAS: Biomarkers, Tumor Funding details: Ministero della Salute Funding details: Fonds Wetenschappelijk Onderzoek, FWO Funding details: Bundesministerium f{\"u}r Bildung und Forschung, BMBF Funding details: Narodowe Centrum Bada{\'n} i Rozwoju, NCBR Funding details: Institut National Du Cancer, INCa Funding details: Instituto de Salud Carlos III, ISCIII Funding details: Ministrstvo za Izobra{\v z}evanje, Znanost in {\v S}port Funding text 1: The use of NT in Italy is limited and variable. There are no signs of greater use in hospitals with more advanced care. Breast cancer neoadjuvant therapy multidisciplinary edited-state corrected-proof The authors thank the participating cancer registries for collecting and preparing the data as part of their role in cancer control. Declaration of conflicting interest The authors declare that there is no conflict of interest. Funding This work was carried out in the framework of HIGHCARE: High-resolution project on prognosis and care of cancer patients (PI Milena Sant), supported in part by ERA-NET in the framework of the call on “Translational research on tertiary prevention in cancer patients” (TRANSCAN), with funding from Ministry of Health, Italy; Research Foundation Flanders (FWO), Belgium; Institut National du Cancer, France; Federal Ministry of Education and Research (BMBF), Germany; Naradowe Centrum Bada{\'n} i Rozwoju, Poland; Ministry of Education, Science and Sport (MIZS), Slovenia; and Instituto de Salud Carlos III, Spain. ORCID iD Lucia Mangone https://orcid.org/0000-0003-4850-2678 References: Aiom, A., Fondazione, A.I.O.M., (2017) I Numeri del Cancro in Italia 2017: Il Pensiero Scientifico Editore, , Roma, AIOM, AIRTUM, Fondazione AIOM; (2010), 7th edition, Hoboken, NJ, Blackwell Publishing; Coviello, V., Buzzoni, C., Fusco, M., Survival of cancer patients in Italy (2017) Epidemiol Prev, 41, pp. 1-244; Plevritis, S.K., Munoz, D., Kurian, A.W., Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000–2012 (2018) JAMA, 319, pp. 154-164; Broeders, M., Moss, S., Nystr{\"o}m, L., The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies (2012) J Med Screen, 19, pp. 14-25; Crocetti, E., Gori, S., Falcini, F., Metastatic breast cancers: estimates for Italy (2018) Tumori, 104, pp. 116-120; Cortazar, P., Zhang, L., Untch, M., Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) Lancet, 384, pp. 164-172; Senkus, E., Kyriakides, S., Ohno, S., Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2015) Ann Oncol, 26, pp. v8-v30; (2018) Clinical Practice Guidelines in Oncology, Breast Cancer, Version 1, , Fort Washington, PA, NCCN; (2017) Linee Guida Neoplasie della Mammella, Edizione 2017, , Milan, Associazione Italiana di Oncologia Medica; Perry, N., Broeders, M., de Wolf, C., T{\"o}rnberg, S., Holland, R., von Karsa, L., European guidelines for quality assurance in breast cancer screening and diagnosis; fourth edition, summary document (2008) Ann Oncol, 19, pp. 614-622; (2000) The Requirements of a Specialist Breast Unit: EUSOMA, , Milan, EUSOMA; Mohiuddin, J.J., Deal, A.M., Carey, L.A., Neoadjuvant systemic therapy use for younger patients with breast cancer treated in different types of cancer centers across the United States (2016) J Am Coll Surg, 223, pp. 717-728; http://www.hrstudies.eu, accessed 15 October, 2018; Fisher, B., Brown, A., Mamounas, E., Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 (1997) J Clin Oncol, 15, pp. 2483-2493; van der Hage, J.A., van de Velde, C.J., Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 (2001) J Clin Oncol, 19, pp. 4224-4237; Vicini, E., Invento, A., Cuoghi, M., Neoadjuvant systemic treatment for breast cancer in Italy: The Italian Society of Surgical Oncology (SICO) Breast Oncoteam survey (2018) Eur J Surg Oncol, 44, pp. 1157-1163; Mougalian, S.S., Soulos, P.R., Killelea, B.K., Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States (2015) Cancer, 121, pp. 2544-2552; Clifton, K., Gutierrez-Barrera, A., Ma, J., Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations (2018) Breast Cancer Res Treat, 170, pp. 101-109; Turchetti, D., Mangone, L., Negri, R., Changes in breast cancer incidence and stage distribution in Modena, Italy: the effect of a mammographic screening program (2002) Cancer Causes Control, 13, pp. 729-734; Zdenkowski, N., Butow, P., Spillane, A., Single-arm longitudinal study to evaluate a decision aid for women offered neoadjuvant systemic therapy for operable breast cancer (2018) J Natl Compr Canc Netw, 16, pp. 378-385",
year = "2019",
month = dec,
day = "1",
doi = "10.1177/0300891619869505",
language = "English",
volume = "105",
pages = "488--493",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",
}